Skip to main content

Colchicine Benefits COVID-19 Patients

A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes.

Efficacy and safety must be determined in controlled clinical trials.he outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with ‘standard-of-care’ (SoC).

In a single center study from northern Italy, 140 COVID-19 inpatients were treated with standard of care (SoC: hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). These were compared with 122 consecutive inpatients who also received colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction).

Colchicine treated patients had a better survival rate at 21 days (84.2% vs 63.6%, p=0.001) compared with SOC only.

A lower risk of death was associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas a higher mortality risk was seen with older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry.

 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject